Clinical genitourinary cancer
Does Physician Documentation of Patients' Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?
Alicia K Morgans, Maelys Touya, Nader El-Chaar, Dina ElSouda, Lisa Mucha, Krishnan Ramaswamy, Kelechi L Adejumo, Tammy Schuler, Jason Sharpe, Bruce Feinberg, Parisa Asgarisabet, Prathamesh Pathak, Stephen J Freedland
Published: 202610.1016/j.clgc.2025.102496
Abstract
INTRODUCTION: Nearly half of patients with prostate cancer experience biochemical recurrence (BCR) within 10 years after definitive treatment. Among them, patients with high-risk BCR are those who have a prostate-specific antigen (PSA) doubling time…
Preview only. Read the full abstract at the source